Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

Ryan J. Sullivan, MD, of Massachusetts General Hospital

Ryan Sullivan, MD, is director of the Center for Melanoma at Massachusetts General Hospital.

Articles by Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

Treatment Optimization for Patients With Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Future Treatment Landscape for Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Promising Late-Stage Trials in Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Targeted Therapy Versus IO for Relapsed/Refractory Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Novel Approaches for Relapsed/Refractory Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Management of Brain Metastases in Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

I/O Dosing Schedules in Metastatic Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Novel Therapies for Metastatic Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Systemic Therapy for Metastatic Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Adjuvant Therapy for Melanoma: Safety and Efficacy

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Adjuvant Therapy for Melanoma: Ongoing Studies of Interest

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Adjuvant Data Explored for Locally Advanced Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Neoadjuvant Data Explored for Locally Advanced Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

pCR and Neoadjuvant Therapy for Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Molecular Testing in Locally Advanced Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Identifying Patients for Neoadjuvant Melanoma Therapy

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Optimal Management of Locally Advanced Melanoma

ByJeffrey S. Weber, MD, PhD, NYU Langone Health,Sunandana Chandra, MD, Northwestern Medicine,Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center,Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

June 23rd 2020

Latest Updated Articles

Identifying Patients for Neoadjuvant Melanoma Therapy
June 23rd 2020
Systemic Therapy for Metastatic Melanoma
June 23rd 2020
Molecular Testing in Locally Advanced Melanoma
June 23rd 2020
Optimal Management of Locally Advanced Melanoma
June 23rd 2020
$Novel Approaches for Relapsed/Refractory Melanoma$
Novel Approaches for Relapsed/Refractory Melanoma
June 23rd 2020
Novel Therapies for Metastatic Melanoma
June 23rd 2020

Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

Articles by Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center

Treatment Optimization for Patients With Melanoma

Future Treatment Landscape for Melanoma

Promising Late-Stage Trials in Melanoma

Targeted Therapy Versus IO for Relapsed/Refractory Melanoma

Novel Approaches for Relapsed/Refractory Melanoma

Management of Brain Metastases in Melanoma

I/O Dosing Schedules in Metastatic Melanoma

Novel Therapies for Metastatic Melanoma

Systemic Therapy for Metastatic Melanoma

Adjuvant Therapy for Melanoma: Safety and Efficacy

Adjuvant Therapy for Melanoma: Ongoing Studies of Interest

Adjuvant Data Explored for Locally Advanced Melanoma

Neoadjuvant Data Explored for Locally Advanced Melanoma

pCR and Neoadjuvant Therapy for Melanoma

Molecular Testing in Locally Advanced Melanoma

Identifying Patients for Neoadjuvant Melanoma Therapy

Optimal Management of Locally Advanced Melanoma

Latest Updated Articles

Trending on OncLive

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS

Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles

Dr Marvin-Peek on the Significance of Efficacy Data for Azacitidine/Ivosidenib/Venetoclax in IDH1-Mutated AML